Literature DB >> 30352259

The impact of histone post-translational modifications in neurodegenerative diseases.

Samantha N Cobos1, Seth A Bennett2, Mariana P Torrente3.   

Abstract

Every year, neurodegenerative disorders take more than 5000 lives in the US alone. Cures have not yet been found for many of the multitude of neuropathies. The majority of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Parkinson's disease (PD) cases have no known genetic basis. Thus, it is evident that contemporary genetic approaches have failed to explain the etiology or etiologies of ALS/FTD and PD. Recent investigations have explored the potential role of epigenetic mechanisms in disease development. Epigenetics comprises heritable changes in gene utilization that are not derived from changes in the genome. A main epigenetic mechanism involves the post-translational modification of histones. Increased knowledge of the epigenomic landscape of neurodegenerative diseases would not only further our understanding of the disease pathologies, but also lead to the development of treatments able to halt their progress. Here, we review recent advances on the association of histone post-translational modifications with ALS, FTD, PD and several ataxias.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Epigenetics; Friedreich's ataxia; Frontotemporal dementia; Histones; Neurodegeneration; Neurodegenerative disease; Parkinson's disease; Post translational modifications; Spinocerebellar ataxia

Mesh:

Substances:

Year:  2018        PMID: 30352259      PMCID: PMC6475498          DOI: 10.1016/j.bbadis.2018.10.019

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  148 in total

Review 1.  Translating the histone code.

Authors:  T Jenuwein; C D Allis
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

2.  Deacetylation of p53 modulates its effect on cell growth and apoptosis.

Authors:  J Luo; F Su; D Chen; A Shiloh; W Gu
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

3.  Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides.

Authors:  Xing Zhang; Xiaodong Cheng
Journal:  Structure       Date:  2003-05       Impact factor: 5.006

Review 4.  Heterochromatin and epigenetic control of gene expression.

Authors:  Shiv I S Grewal; Danesh Moazed
Journal:  Science       Date:  2003-08-08       Impact factor: 47.728

5.  An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8)

Authors:  M D Koob; M L Moseley; L J Schut; K A Benzow; T D Bird; J W Day; L P Ranum
Journal:  Nat Genet       Date:  1999-04       Impact factor: 38.330

6.  Phosphorylation of serine 10 in histone H3 is functionally linked in vitro and in vivo to Gcn5-mediated acetylation at lysine 14.

Authors:  W S Lo; R C Trievel; J R Rojas; L Duggan; J Y Hsu; C D Allis; R Marmorstein; S L Berger
Journal:  Mol Cell       Date:  2000-06       Impact factor: 17.970

7.  The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis.

Authors:  C Debove; P Zeisser; P M Salzman; L K Powe; P Truffinet
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2001-09

8.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1.

Authors:  Manabu Funayama; Kazuko Hasegawa; Hisayuki Kowa; Masaaki Saito; Shoji Tsuji; Fumiya Obata
Journal:  Ann Neurol       Date:  2002-03       Impact factor: 10.422

Review 9.  Inhibition of histone deacetylase activity by butyrate.

Authors:  James R Davie
Journal:  J Nutr       Date:  2003-07       Impact factor: 4.798

10.  Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin.

Authors:  Bernhard Lehnertz; Yoshihide Ueda; Alwin A H A Derijck; Ulrich Braunschweig; Laura Perez-Burgos; Stefan Kubicek; Taiping Chen; En Li; Thomas Jenuwein; Antoine H F M Peters
Journal:  Curr Biol       Date:  2003-07-15       Impact factor: 10.834

View more
  11 in total

Review 1.  The Essential Role of Epigenetic Modifications in Neurodegenerative Diseases with Dyskinesia.

Authors:  Zhipeng Qi; Jiashuo Li; Minghui Li; Xianchao Du; Lei Zhang; Shuang Wang; Bin Xu; Wei Liu; Zhaofa Xu; Yu Deng
Journal:  Cell Mol Neurobiol       Date:  2021-08-12       Impact factor: 4.231

2.  Downregulation of glob1 mitigates human tau mediated neurotoxicity by restricting heterochromatin loss and elevating the autophagic response in drosophila.

Authors:  Surajit Sarkar
Journal:  Mol Biol Rep       Date:  2022-05-28       Impact factor: 2.742

Review 3.  Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing.

Authors:  Stephen C Cunnane; Mark J Millan; Eugenia Trushina; Cecilie Morland; Alessandro Prigione; Gemma Casadesus; Zane B Andrews; M Flint Beal; Linda H Bergersen; Roberta D Brinton; Suzanne de la Monte; Anne Eckert; Jenni Harvey; Ross Jeggo; Jack H Jhamandas; Oliver Kann; Clothide Mannoury la Cour; William F Martin; Gilles Mithieux; Paula I Moreira; Michael P Murphy; Klaus-Armin Nave; Tal Nuriel; Stéphane H R Oliet; Frédéric Saudou; Mark P Mattson; Russell H Swerdlow
Journal:  Nat Rev Drug Discov       Date:  2020-07-24       Impact factor: 84.694

4.  p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR).

Authors:  Maya Maor-Nof; Zohar Shipony; Rodrigo Lopez-Gonzalez; Lisa Nakayama; Yong-Jie Zhang; Julien Couthouis; Jacob A Blum; Patricia A Castruita; Gabriel R Linares; Kai Ruan; Gokul Ramaswami; David J Simon; Aviv Nof; Manuel Santana; Kyuho Han; Nasa Sinnott-Armstrong; Michael C Bassik; Daniel H Geschwind; Marc Tessier-Lavigne; Laura D Attardi; Thomas E Lloyd; Justin K Ichida; Fen-Biao Gao; William J Greenleaf; Jennifer S Yokoyama; Leonard Petrucelli; Aaron D Gitler
Journal:  Cell       Date:  2021-01-21       Impact factor: 66.850

5.  HAT cofactor TRRAP modulates microtubule dynamics via SP1 signaling to prevent neurodegeneration.

Authors:  Alicia Tapias; David Lázaro; Bo-Kun Yin; Seyed Mohammad Mahdi Rasa; Anna Krepelova; Erika Kelmer Sacramento; Paulius Grigaravicius; Philipp Koch; Joanna Kirkpatrick; Alessandro Ori; Francesco Neri; Zhao-Qi Wang
Journal:  Elife       Date:  2021-02-17       Impact factor: 8.140

Review 6.  Epigenetic Modulation of Microglia Function and Phenotypes in Neurodegenerative Diseases.

Authors:  Li Wang; Chao-Chao Yu; Xin-Yuan Liu; Xiao-Ni Deng; Qing Tian; Yan-Jun Du
Journal:  Neural Plast       Date:  2021-05-29       Impact factor: 3.599

Review 7.  Atypical Ubiquitination and Parkinson's Disease.

Authors:  Olga Buneeva; Alexei Medvedev
Journal:  Int J Mol Sci       Date:  2022-03-28       Impact factor: 5.923

8.  VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes.

Authors:  Elena Martín-Doncel; Ana M Rojas; Lara Cantarero; Pedro A Lazo
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

Review 9.  Exosomal miRNAs as Potential Diagnostic Biomarkers in Alzheimer's Disease.

Authors:  Ida Manna; Selene De Benedittis; Andrea Quattrone; Domenico Maisano; Enrico Iaccino; Aldo Quattrone
Journal:  Pharmaceuticals (Basel)       Date:  2020-09-12

10.  Insights into the Role of the Microbiota and of Short-Chain Fatty Acids in Rubinstein-Taybi Syndrome.

Authors:  Elisabetta Di Fede; Emerenziana Ottaviano; Paolo Grazioli; Camilla Ceccarani; Antonio Galeone; Chiara Parodi; Elisa Adele Colombo; Giulia Bassanini; Grazia Fazio; Marco Severgnini; Donatella Milani; Elvira Verduci; Thomas Vaccari; Valentina Massa; Elisa Borghi; Cristina Gervasini
Journal:  Int J Mol Sci       Date:  2021-03-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.